These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38045348)

  • 1. Chimerization of the Anti-Viral CD8
    Vile R; Webb M; van Vloten J; Evgin L; Sangsuwannukul T; Kendall B; Tonne J; Thompson J; Metko M; Moore M; Yerovi MC; McNiven M; Monga S; Borad M; Roberts L
    Res Sq; 2023 Nov; ():. PubMed ID: 38045348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
    Webb MJ; Sangsuwannukul T; van Vloten J; Evgin L; Kendall B; Tonne J; Thompson J; Metko M; Moore M; Chiriboga Yerovi MP; Olin M; Borgatti A; McNiven M; Monga SPS; Borad MJ; Melcher A; Roberts LR; Vile R
    Nat Commun; 2024 Jun; 15(1):5442. PubMed ID: 38937436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
    Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
    Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.
    Shim KG; Zaidi S; Thompson J; Kottke T; Evgin L; Rajani KR; Schuelke M; Driscoll CB; Huff A; Pulido JS; Vile RG
    Mol Ther; 2017 Apr; 25(4):962-975. PubMed ID: 28237836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis.
    Lin J; Liu F; Gao F; Chen Y; Wang R; Wang X; Li Y; Li Q; Sun S; Li Z; Lan Y; Lu H; Guo W; Du L; Gao F; Song D; Zhao K; Guan J; He W
    Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166538. PubMed ID: 36096276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP.
    Vijver SV; Danklmaier S; Pipperger L; Gronauer R; Floriani G; Hackl H; Das K; Wollmann G
    Front Immunol; 2022; 13():1100730. PubMed ID: 36741416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model.
    Tang S; Shi L; Luker BT; Mickler C; Suresh B; Lesinski GB; Fan D; Liu Y; Luo M
    Virol J; 2022 Feb; 19(1):32. PubMed ID: 35197076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
    Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.
    Wang G; Kang X; Chen KS; Jehng T; Jones L; Chen J; Huang XF; Chen SY
    Nat Commun; 2020 Mar; 11(1):1395. PubMed ID: 32170083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
    Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R
    Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.